MBX Biosciences, Inc. (MBX)
↓ Download CSVKey ratios (FY2025)
-23.6%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Income | -$98.06M | -$68.19M | -$35.31M | — |
| Net Income | -$86.97M | -$61.92M | -$32.56M | — |
| EPS (Diluted) | $-2.38 | $-5.82 | $-31.96 | — |
| Total Assets | $385.14M | $268.54M | $84.18M | — |
| Total Liabilities | $15.92M | $11.09M | $4.29M | — |
| Shareholders' Equity | $369.22M | $257.44M | -$72.47M | -$42.60M |
| Cash & Equivalents | $75.29M | $49.35M | $30.52M | — |
| Operating Cash Flow | -$79.95M | -$54.68M | -$31.98M | — |
| Capital Expenditures | $1.93M | $874.0K | $129.0K | — |
| Shares Outstanding | 44.93M | 33.42M | 1.26M | — |